市場調査レポート
商品コード
1604757

自己免疫疾患治療薬市場:製品、用途別-2025-2030年の世界予測

Autoimmune Disease Therapeutics Market by Product (Diagnostic Equipment, Drugs), Application (Localized Autoimmune Diseases, Systemic Autoimmune Diseases) - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 197 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.81円
自己免疫疾患治療薬市場:製品、用途別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

自己免疫疾患治療薬市場は、2023年に1,989億9,000万米ドルと評価され、2024年には2,145億4,000万米ドルに達すると予測され、CAGR 7.90%で成長し、2030年には3,390億米ドルに達すると予測されています。

自己免疫疾患治療薬市場には、身体の免疫系が誤って自身の組織を攻撃する自己免疫疾患の管理と緩和を目的とした治療薬や医薬品が含まれます。これらの治療薬の必要性は、関節リウマチ、ループス、多発性硬化症などの自己免疫疾患の有病率の増加によってもたらされ、高度な医療介入が求められています。これらの治療薬の用途は、生物学的製剤や免疫抑制剤からモノクローナル抗体まで多岐にわたり、免疫系の特定成分を標的として症状を緩和し、患者の転帰を改善します。最終用途には、自己免疫疾患の管理に特化した病院、診療所、専門センターが含まれます。

主な市場の統計
基準年[2023] 1,989億9,000万米ドル
推定年[2024] 2,145億4,000万米ドル
予測年[2030] 3,390億米ドル
CAGR(%) 7.90%

この市場に影響を与える主な成長要因には、バイオテクノロジーの進歩、自己免疫疾患に対する意識の高まり、新規治療のための研究開発投資の増加などがあります。また、個別化医療の台頭も、治療法を個人の遺伝子プロファイルに合わせることができるため、成長を後押ししています。医療インフラが整備され、利用しやすい治療法への需要が高まっている新興市場にはビジネスチャンスがあります。製薬企業と研究機関の共同研究は、画期的な治療法につながる可能性があります。企業は市場シェアを獲得するため、薬剤の有効性と安全性プロファイルの向上に注力しなければならないです。

しかし、高額な治療費、厳しい規制の枠組み、長期服用に伴う潜在的な副作用などの課題も残っています。さらに、疾病メカニズムの理解が限られていることが、画期的な進歩を妨げています。革新は遺伝子治療と副作用の少ないより精密な生物製剤の開発に焦点を当てるべきです。遠隔医療やデジタル治療などのデジタル・ヘルス・ソリューションは、患者のモニタリングや治療へのアドヒアランスを高めることができます。

全体として、市場はダイナミックであり、技術の進歩とヘルスケア政策の強化に支えられた力強い成長が見込まれます。持続可能な事業成長のためには、企業は規制の複雑さや科学的課題を乗り越えながら、治療効果、費用対効果、患者のQOLを向上させるイノベーションを活用しなければならないです。精密医療とデジタルヘルスの動向を認識し統合することで、市場のさらなる拡大とイノベーションを促進することができます。

市場力学:急速に進化する自己免疫疾患治療薬市場の主要市場インサイトを公開

自己免疫疾患治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の自己免疫疾患の流行
    • 医療インフラの急速な改善と患者の意識レベルの上昇
    • いくつかの自己免疫診断検査を容易にするための検査室の自動化
  • 市場抑制要因
    • 高コストと治療結果の不確実性
  • 市場機会
    • 政府機関や非営利団体による資金提供の増加
    • 自己免疫疾患の標的療法の出現
  • 市場の課題
    • 自己免疫疾患免疫療法の副作用

ポーターのファイブフォース:自己免疫疾患治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:自己免疫疾患治療薬市場における外部からの影響の把握

外部マクロ環境要因は、自己免疫疾患治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析自己免疫疾患治療薬市場における競合情勢の把握

自己免疫疾患治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス自己免疫疾患治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、自己免疫疾患治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨自己免疫疾患治療薬市場における成功への道筋を描く

自己免疫疾患治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で自己免疫疾患の罹患率が増加
      • ヘルスケアインフラの急速な改善と患者の意識の高まり
      • 複数の自己免疫診断検査を容易にする検査室の自動化
    • 抑制要因
      • 治療費が高く、治療結果が不確実である
    • 機会
      • 政府機関や非営利団体による資金援助の増加
      • 自己免疫疾患に対する標的治療法の出現
    • 課題
      • 自己免疫疾患免疫療法の副作用
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 自己免疫疾患治療薬市場:製品別

  • 診断機器
  • 薬物
    • アミノサリチル酸または5-ASA
    • アントラリン
    • アボネックス
    • ベタセロン
    • カリシポトリエン
    • コパキソン
    • コルチコステロイド
    • グルココルチコイド
    • ヒドロキシクロロキン
    • メトトレキサート
    • 非ステロイド性抗炎症薬
    • レビフ

第7章 自己免疫疾患治療薬市場:用途別

  • 局所性自己免疫疾患
  • 全身性自己免疫疾患

第8章 南北アメリカの自己免疫疾患治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の自己免疫疾患治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの自己免疫疾患治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB S.A.
  • Werfen S.A.
図表

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES OR 5-ASA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTHRALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AVONEX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BETASERON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CALICIPOTRIENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COPAXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTERIODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REBIF, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 154. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-030C42D3EDB7

The Autoimmune Disease Therapeutics Market was valued at USD 198.99 billion in 2023, expected to reach USD 214.54 billion in 2024, and is projected to grow at a CAGR of 7.90%, to USD 339.00 billion by 2030.

The Autoimmune Disease Therapeutics market encompasses treatments and pharmaceuticals aimed at managing and mitigating autoimmune disorders, where the body's immune system mistakenly attacks its own tissues. The necessity for these therapeutics is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, demanding advanced medical interventions. Application of these therapeutics ranges from biologics and immunosuppressants to monoclonal antibodies, targeting specific components of the immune system to alleviate symptoms and improve patient outcomes. End-use involves hospitals, clinics, and specialty centers dedicated to managing autoimmune conditions.

KEY MARKET STATISTICS
Base Year [2023] USD 198.99 billion
Estimated Year [2024] USD 214.54 billion
Forecast Year [2030] USD 339.00 billion
CAGR (%) 7.90%

Key growth factors influencing this market include advancements in biotechnology, heightened awareness of autoimmune diseases, and increased investment in R&D for novel treatments. The rise in personalized medicine also propels growth, as therapies can be tailored to individual genetic profiles. Opportunities lie in emerging markets with growing healthcare infrastructure, coupled with the demand for accessible therapies. Collaborations between pharmaceutical companies and research institutions can lead to breakthrough treatments. Companies must focus on enhancing drug efficacy and safety profiles to capture market share.

However, challenges persist, such as high treatment costs, stringent regulatory frameworks, and potential side effects associated with long-term medication use. Limited understanding of disease mechanisms further hinders breakthrough advancements. Innovations should focus on gene therapies and the development of more precise biologics with fewer side effects. Digital health solutions like telemedicine and digital therapeutics can enhance patient monitoring and adherence to treatments.

Overall, the market is dynamic, with robust growth prospects supported by technological advances and healthcare policy enhancements. For sustainable business growth, companies must leverage innovations that improve therapeutic efficacy, cost-effectiveness, and patient quality of life while navigating regulatory complexities and scientific challenges. Recognizing and integrating trends in precision medicine and digital health can catalyze further market expansion and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autoimmune Disease Therapeutics Market

The Autoimmune Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of autoimmune diseases across the globe
    • Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
    • Automation of laboratories to ease several autoimmune diagnostic tests
  • Market Restraints
    • High cost and uncertain outcomes of the treatment
  • Market Opportunities
    • Increasing funding by government associations and non-profit organizations
    • Emergence of target therapies for autoimmune disease
  • Market Challenges
    • Side effects of autoimmune diseases immunotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Autoimmune Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autoimmune Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autoimmune Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autoimmune Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autoimmune Disease Therapeutics Market

A detailed market share analysis in the Autoimmune Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autoimmune Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autoimmune Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autoimmune Disease Therapeutics Market

A strategic analysis of the Autoimmune Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, bioMerieux S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Exagen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, UCB S.A., and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Diagnostic Equipment and Drugs. The Drugs is further studied across Aminosalicylates or 5-ASA, Anthralin, Avonex, Betaseron, Calicipotriene, Copaxone, Corticosteriods, Glucocorticoids, Hydroxychloroquine, Methotrexate, Non-steroidal Anti-inflammatory Drugs, and Rebif.
  • Based on Application, market is studied across Localized Autoimmune Diseases and Systemic Autoimmune Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of autoimmune diseases across the globe
      • 5.1.1.2. Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
      • 5.1.1.3. Automation of laboratories to ease several autoimmune diagnostic tests
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and uncertain outcomes of the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding by government associations and non-profit organizations
      • 5.1.3.2. Emergence of target therapies for autoimmune disease
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of autoimmune diseases immunotherapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostic Equipment
  • 6.3. Drugs
    • 6.3.1. Aminosalicylates or 5-ASA
    • 6.3.2. Anthralin
    • 6.3.3. Avonex
    • 6.3.4. Betaseron
    • 6.3.5. Calicipotriene
    • 6.3.6. Copaxone
    • 6.3.7. Corticosteriods
    • 6.3.8. Glucocorticoids
    • 6.3.9. Hydroxychloroquine
    • 6.3.10. Methotrexate
    • 6.3.11. Non-steroidal Anti-inflammatory Drugs
    • 6.3.12. Rebif

7. Autoimmune Disease Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Localized Autoimmune Diseases
  • 7.3. Systemic Autoimmune Diseases

8. Americas Autoimmune Disease Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Autoimmune Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Beckman Coulter, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioAgilytix Labs, LLC
  • 8. bioMerieux S.A.
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Exagen, Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Johnson & Johnson Services, Inc.
  • 15. Lupin Limited
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer, Inc.
  • 19. Sanofi S.A.
  • 20. Siemens Healthineers AG
  • 21. Thermo Fisher Scientific Inc.
  • 22. Trinity Biotech PLC
  • 23. UCB S.A.
  • 24. Werfen S.A.